COVID-19 rapid evidence summary: Tocilizumab for COVID-19, NICE (updated 24th February 2021)
Evidence summary updated at the request of NHS England because new evidence was identified: prepublication study results from the nationally prioritised platform study (Horby et al. 2021; the RECOVERY study), and a published randomised controlled trial (Veiga et al. 2021). (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - March 1, 2021 Category: Consumer Health News Source Type: news

Repurposed arthritis drug did not significantly improve severe COVID-19 pneumonia
(University of California - San Diego) A repurposed drug used to treat arthritis did not significantly improve the outcomes of patients with severe COVID-19 pneumonia. Tocilizumab did not significantly improve clinical status or mortality rate at 28 days for participants who received it compared to a placebo. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - March 1, 2021 Category: Infectious Diseases Source Type: news

Tocilizumab May Improve Lung Function in Early Systemic Sclerosis Tocilizumab May Improve Lung Function in Early Systemic Sclerosis
Treatment with tocilizumab could stabilize or improve lung function in people with early interstitial lung disease associated with systemic sclerosis.Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - February 19, 2021 Category: Dermatology Tags: Rheumatology News Source Type: news

UK Interim Clinical Commissioning Policy for tocilizumab has been updated to cover a wider group of hospitalised COVID-19 positive patients, DHSC
NHS trusts/health boards are recommended to consider prescribing single dose of tocilizumab to eligible hospitalised patients with COVID-19 pneumonia, typically as adjuvant treatment to dexamethasone as standard of care, following announcement of findings of RECOVERY trial. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - February 19, 2021 Category: Consumer Health News Source Type: news

Coronavirus update: Tocilizumab is a life-saving treatment for severely ill patients
CORONAVIRUS is being attacked from all angles, with game-changing treatments driving down the fatality rate in hospitals. In a press briefing on Monday, the government's Chief Medical Officer suggests arthritis drug tocilizumab strengthens the fight against COVID-19. (Source: Daily Express - Health)
Source: Daily Express - Health - February 15, 2021 Category: Consumer Health News Source Type: news

COVID-19 rapid guideline: critical care in adults [NG159], NICE (updated 12th February 2021)
Updated On 12 February 2021, we added advice to follow NHS England ' s interim clinical commissioning policies on tocilizumab and sarilumab for treating critically ill patients with COVID-19 pneumonia. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - February 12, 2021 Category: Consumer Health News Source Type: news

New coronavirus drug: What is life-saving drug Tocilizumab?
A DRUG normally used for arthritis has provided hope for coronavirus patients in hospital. What is life-saving drug Tocilizumab? (Source: Daily Express - Health)
Source: Daily Express - Health - February 11, 2021 Category: Consumer Health News Source Type: news

Roche arthritis drug cuts deaths in hospitalized COVID-19 patients, study suggests
Roche's arthritis drug tocilizumab cuts the risk of death among patients hospitalized with severe COVID-19, also shortening the time to recovery and reducing the need for mechanical ventilation, a large clinical trial suggests. (Source: CBC | Health)
Source: CBC | Health - February 11, 2021 Category: Consumer Health News Tags: News/Health Source Type: news

Roche's Tocilizumab Cuts Deaths in Hospitalized COVID-19 Patients: Study Roche's Tocilizumab Cuts Deaths in Hospitalized COVID-19 Patients: Study
Roche ' s arthritis drug tocilizumab cuts the risk of death among patients hospitalized with severe COVID-19, also shortening the time to recovery and reducing the need for mechanical ventilation, results of a large trial showed on Thursday.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 11, 2021 Category: Consumer Health News Tags: Infectious Diseases News Source Type: news

Injected arthritis drug reduces risk of death from Covid-19 by 4%, study finds
The drug tocilizumab is used by rheumatoid arthritis patients in the UK because it can control swelling inside the body. It costs around £615 per four-week dose when used for that purpose. (Source: the Mail online | Health)
Source: the Mail online | Health - February 11, 2021 Category: Consumer Health News Source Type: news

Arthritis drug that helps Covid ICU patients has wider benefits, trial finds
Researchers say tocilizumab could also help patients on general wards and relieve pressure on NHSCoronavirus – latest updatesSee all our coronavirus coverageA rheumatoid arthritis drug previously found to save lives among intensive care patients with Covid could also help those receiving oxygen on general wards and reduce pressure on the NHS, researchers have found.A trial calledRemap-Cap revealed last month that the anti-inflammatory drugtocilizumab cut both the risk of death among Covid patients in intensive care and the length of time patients spent in such units.Continue reading... (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - February 11, 2021 Category: Science Authors: Nicola Davis Tags: Coronavirus Medical research UK news World news Source Type: news

Arthritis drug saves lives and speeds recovery from Covid-19, trial shows
Tocilizumab cuts mortality risk by 15%, reduces need for ventilation and shortens time in hospital (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - February 11, 2021 Category: Pharmaceuticals Source Type: news

Arthritis drug tocilizumab cuts deaths from Covid
Giving it along with a steroid drug can help the sickest patients with Covid-19, research reveals. (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - February 11, 2021 Category: Consumer Health News Source Type: news

Treatment of critically ill adults with Covid-19 pneumonia
Interim clinical commissioning policies are now available for tocilizumab and sarilumab for the treatment of critically ill adults with COVID-19 pneumonia. (Source: NHS Networks)
Source: NHS Networks - February 4, 2021 Category: UK Health Source Type: news

Interleukin-6 inhibitors (tocilizumab and sarilumab) for critically ill patients with COVID-19 pneumonia (adults), MHRA (published 1st February 2021)
NHS trusts / health boards are recommended to consider prescribing either tocilizumab or sarilumab to hospitalised patients being treated with non-invasive ventilation (high-flow nasal oxygen therapy or continuous positive airway pressure ventilation) or invasive mechanical. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - February 2, 2021 Category: Consumer Health News Source Type: news